Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic
- PMID: 18498241
- DOI: 10.1086/588673
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic
Abstract
We developed a mathematical model using a multiple source of infection framework to assess the potential effect of the expansion of highly active antiretroviral therapy (HAART) coverage among those in medical need on the number of individuals testing newly positive for human immunodeficiency virus (HIV) and on related costs in British Columbia, Canada, over the next 25 years. The model was calibrated using retrospective data describing antiretroviral therapy utilization and individuals testing newly positive for HIV in the province. Different scenarios were investigated on the basis of varying assumptions regarding drug resistance, adherence to HAART, therapeutic guidelines, degree of HAART coverage, and the timing of HAART uptake. Expansion of HAART lead to substantial reductions in the growth of the HIV epidemic and related costs. These results provide powerful additional motivation to accelerate the roll out of HAART programs aggressively targeting those in medical need, both for their own benefit and as a means of decreasing new HIV infections.
Similar articles
-
When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.Antivir Ther. 2008;13(2):241-51. Antivir Ther. 2008. PMID: 18505175
-
Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.Antivir Ther. 2004 Feb;9(1):27-36. Antivir Ther. 2004. PMID: 15040534
-
Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.AIDS. 2008 Nov 12;22(17):2371-80. doi: 10.1097/QAD.0b013e328315cdd3. AIDS. 2008. PMID: 18981777
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
-
CD4 cell count-guided treatment interruption: be smart and wait for more evidence.Clin Infect Dis. 2005 Mar 1;40(5):735-7. doi: 10.1086/427885. Epub 2005 Feb 4. Clin Infect Dis. 2005. PMID: 15714421 Review. No abstract available.
Cited by
-
Estimation of HIV-testing rates to maximize early diagnosis-derived benefits at the individual and population level.PLoS One. 2013;8(1):e53193. doi: 10.1371/journal.pone.0053193. Epub 2013 Jan 7. PLoS One. 2013. PMID: 23308161 Free PMC article.
-
A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa.AIDS Patient Care STDS. 2015 May;29(5):299-306. doi: 10.1089/apc.2014.0293. Epub 2015 Feb 18. AIDS Patient Care STDS. 2015. PMID: 25692575 Free PMC article.
-
HIV treatment as prevention: the utility and limitations of ecological observation.PLoS Med. 2012;9(7):e1001260. doi: 10.1371/journal.pmed.1001260. Epub 2012 Jul 10. PLoS Med. 2012. PMID: 22802740 Free PMC article. Review.
-
How HIV treatment could result in effective prevention.Future Virol. 2010 Jul;5(4):405-415. doi: 10.2217/fvl.10.38. Future Virol. 2010. PMID: 20814447 Free PMC article.
-
InterVA versus Spectrum: how comparable are they in estimating AIDS mortality patterns in Nairobi's informal settlements?Glob Health Action. 2013 Oct 23;6:21638. doi: 10.3402/gha.v6i0.21638. Glob Health Action. 2013. PMID: 24160914 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical